GLP1R and metabolic dysfunction-associated steatotic liver disease: At the same time, therapies developed with other primary goals can actually be useful in improving hepatic functionality and lipid status, gaining interest also for the treatment of NAFLD, i.e., incretin agonists (GLP-1 in particular) and THRβ agonists.